AR099950A1 - Determinación de polimorfismos de un solo nucleótido de utilidad para la predicción de la respuesta a la rasagilina - Google Patents

Determinación de polimorfismos de un solo nucleótido de utilidad para la predicción de la respuesta a la rasagilina

Info

Publication number
AR099950A1
AR099950A1 ARP150101010A ARP150101010A AR099950A1 AR 099950 A1 AR099950 A1 AR 099950A1 AR P150101010 A ARP150101010 A AR P150101010A AR P150101010 A ARP150101010 A AR P150101010A AR 099950 A1 AR099950 A1 AR 099950A1
Authority
AR
Argentina
Prior art keywords
subject
rasagiline
parkinson
disease
human
Prior art date
Application number
ARP150101010A
Other languages
English (en)
Inventor
MASELLIS Mario
Knight Joanne
Shannon Collinson Maureen
Edward Lang Anthony
Lowery KENNEDY James
Levy Joseph
Tchelet Amir
Grossman Iris
Eyal Eli
Barnett Ofra
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR099950A1 publication Critical patent/AR099950A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Método para tratar un humano sujeto que sufre del mal de Parkinson (PD) con una composición farmacéutica que comprende rasagilina, o una sal farmacéuticamente aceptable de rasagilina, y un vehículo farmacéuticamente aceptable, que comprende los pasos de: (i) obtener una muestra biológica que comprende un genoma del sujeto humano que sufre de mal de Parkinson; (ii) evaluar el ADN o el ARN de la muestra biológica de dicho sujeto humano usando una sonda o un cebador, para determinar el genotipo diploide del sujeto del polimorfismo de un solo nucleótido (SNP) rs1076560 o rs2283265; (iii) identificar el sujeto humano como un respondedor predicho a la rasagilina si el genotipo diploide es CC en rs1076560, CC en rs2283265 o CC en ambos rs1076560 y rs2283265; y (iv) administrar la composición farmacéutica que comprende rasagilina y un vehículo farmacéuticamente aceptable al sujeto humano si dicho sujeto es identificado como un respondedor a la rasagilina. Reivindicación 31: Un conjunto de elementos [kit] de diagnóstico para evaluar la capacidad de respuesta al tratamiento con rasagilina en un sujeto humano que sufre del mal de Parkinson, caracterizado porque dicho conjunto de elementos comprende (i) por lo menos una sonda especifica del SNP rs1076560 o rs2283265, y (ii) instrucciones de uso de dicha por lo menos una sonda a fin de evaluar la capacidad de respuesta del sujeto al tratamiento con rasagilina. Reivindicación 39: Un método para determinar la identidad de los alelos de menos de 10.000 polimorfismos de un solo nucleótido (SNP) en un sujeto seleccionado del grupo de sujetos que consiste en sujetos humanos diagnosticados con el mal de Parkinson para producir un perfil polimórfico del sujeto seleccionado, diagnosticado con el mal de Parkinson, caracterizado porque comprende (i) obtener una muestra biológica que comprende un genoma del sujeto humano seleccionado que fue diagnosticado con el mal de Parkinson; (ii) seleccionar mediante un análisis de identidad alélica por lo menos un SNP ubicado en rs1076560 y un SNP ubicado en rs2283265 en el genoma del sujeto seleccionado que fue diagnosticado con el mal de Parkinson; y (iii) evaluar, con una sonda o un cebador, si a) la identidad alélica en rs1076560 es CC en la secuencia de nucleótidos del genoma en la muestra biológica del paso i), y b) la identidad alélica en rs2283265 es CC en la secuencia de nucleótidos del genoma en la muestra biológica del paso i), y en donde se seleccionaron menos de 10.000 SNP para el análisis de identidad alélica en el paso ii) y los mismos menos de 10.000 SNP se evalúan en el paso iii). Reivindicación 51: Una base de datos física o electrónica, caracterizada porque comprende los perfiles polimórficos de sujetos humanos que sufren de PD, en donde cada perfil polimórfico incluye el genotipo diploide de menos de 10.000 SNP, y dichos menos de 10.000 SNP incluyen rs1076560 y rs36023.
ARP150101010A 2014-04-01 2015-04-01 Determinación de polimorfismos de un solo nucleótido de utilidad para la predicción de la respuesta a la rasagilina AR099950A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461973603P 2014-04-01 2014-04-01

Publications (1)

Publication Number Publication Date
AR099950A1 true AR099950A1 (es) 2016-08-31

Family

ID=54189487

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101010A AR099950A1 (es) 2014-04-01 2015-04-01 Determinación de polimorfismos de un solo nucleótido de utilidad para la predicción de la respuesta a la rasagilina

Country Status (9)

Country Link
US (1) US20150275302A1 (es)
EP (1) EP3126527A4 (es)
JP (1) JP2017517481A (es)
AR (1) AR099950A1 (es)
CA (1) CA2943841A1 (es)
IL (1) IL247824A0 (es)
MX (1) MX2016012718A (es)
TW (1) TW201621051A (es)
WO (1) WO2015153629A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
CN107941953A (zh) * 2017-11-30 2018-04-20 天津生机集团股份有限公司 一种兽药中金刚烷胺药物残留的检测方法
CN109825572A (zh) * 2019-03-13 2019-05-31 陈向东 一种检测与异丙酚的敏感性相关基因多态性的试剂盒及其检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253585A1 (en) * 2005-11-30 2009-10-08 Luda Diatchenko Identification of Genetic Polymorphic Variants Associated With Somatosensory Disorders and Methods of Using the Same
EP2069541A4 (en) * 2006-08-01 2010-05-19 Univ Ohio State Res Found POLYMORPHISMS IN GENES AFFECTING DISORDERS OF THE CENTRAL NERVOUS SYSTEM AND USES THEREOF
NZ589445A (en) * 2008-06-13 2013-06-28 Teva Pharma Rasagiline for parkinson's disease modification
US8835111B2 (en) * 2009-03-12 2014-09-16 Brainco Biopharma S.L. Genotyping tool for improving the prognostic and clinical management of MS patients

Also Published As

Publication number Publication date
CA2943841A1 (en) 2015-10-08
MX2016012718A (es) 2016-12-16
US20150275302A1 (en) 2015-10-01
WO2015153629A1 (en) 2015-10-08
EP3126527A4 (en) 2017-10-04
EP3126527A1 (en) 2017-02-08
TW201621051A (zh) 2016-06-16
JP2017517481A (ja) 2017-06-29
IL247824A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
Weidner et al. Aging of blood can be tracked by DNA methylation changes at just three CpG sites
Maussion et al. Functional DNA methylation in a transcript specific 3′ UTR region of TrkB associates with suicide
Suh et al. Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration
Nagata et al. Association between DNA methylation of the BDNF promoter region and clinical presentation in Alzheimer's disease
AR102518A1 (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40
Kubota-Sakashita et al. A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia
Parisien et al. Effect of human genetic variability on gene expression in dorsal root ganglia and association with pain phenotypes
Van Der Doelen et al. Early life adversity and serotonin transporter gene variation interact to affect DNA methylation of the corticotropin-releasing factor gene promoter region in the adult rat brain
Petit et al. Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder
Dietsche et al. The impact of a CACNA1C gene polymorphism on learning and hippocampal formation in healthy individuals: a diffusion tensor imaging study
Choi et al. A cohort study of MFN2 mutations and phenotypic spectrums in Charcot–Marie–Tooth disease 2A patients
Liang et al. Increased expression of mir-34a-5p and clinical association in acute ischemic stroke patients and in a rat model
CN104293952B (zh) 单核苷酸多态性rs10817758在检测麻风病易感基因中的应用
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
AR099950A1 (es) Determinación de polimorfismos de un solo nucleótido de utilidad para la predicción de la respuesta a la rasagilina
Faber et al. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting
CN104293946A (zh) 单核苷酸多态性rs663743在检测麻风病易感基因中的应用
AR097489A1 (es) Marcadores de riesgo para cardiovasculopatías en pacientes con nefropatía crónica
ES2759507T3 (es) Método para predecir una respuesta de tratamiento a un antagonista de V1B en un paciente con síntomas depresivos y/o de ansiedad
Kiaei et al. Detection of t (8; 14) c-myc/IgH gene rearrangement by long-distance polymerase chain reaction in patients with diffuse large B-cell lymphoma
Rzezniczek et al. Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients
Saadat et al. Genetic polymorphism in the DNA repair gene XRCC1 and susceptibility to schizophrenia
Kaur et al. An exonic G894T variant of endothelial nitric oxide synthase gene as a risk factor for ischemic stroke in North Indians
CN105969863B (zh) 与早产发生相关的mmp-8基因多态性及其检测方法
De Santis et al. Molecular strain typing of Brucella abortus isolates from Italy by two VNTR allele sizing technologies

Legal Events

Date Code Title Description
FB Suspension of granting procedure